PMID- 36578926
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20230509
IS  - 2234-943X (Print)
IS  - 2234-943X (Electronic)
IS  - 2234-943X (Linking)
VI  - 12
DP  - 2022
TI  - Case report: Multicentric Castleman disease as a manifestation of immune 
      reconstitution inflammatory syndrome in Malawi.
PG  - 969135
LID - 10.3389/fonc.2022.969135 [doi]
LID - 969135
AB  - INTRODUCTION: Multicentric Castleman disease (MCD) is a lymphoproliferative 
      disorder characterized by systemic inflammation, lymphadenopathy, and cytopenias. 
      MCD caused by Kaposi sarcoma herpesvirus (MCD-KSHV) frequently arises in the 
      context of HIV. It can be associated with immune reconstitution inflammatory 
      syndrome (IRIS), but MCD-IRIS is rarely reported in sub-Saharan Africa (SSA) 
      where HIV and KSHV infection are common. CASE DESCRIPTION: A 36-year-old woman in 
      Malawi with HIV on antiretroviral therapy (ART) for nine years presented with 
      fatigue, weight loss, and lymphadenopathy. Lymph node biopsy was consistent with 
      HIV lymphadenitis without evident KSHV-MCD and HIV RNA was 4,244 copies/mL. She 
      switched to second-line ART and returned four months later with worsening 
      lymphadenopathy, fever, night sweats, weight loss, and anemia. A repeat lymph 
      node biopsy demonstrated unequivocal KSHV-MCD features not present on the 
      original biopsy. Her repeat HIV viral load was undetectable and she received 
      chemotherapy with subsequent remission on continued ART for 24 months. 
      DISCUSSION: This is among the first reported cases of MCD-IRIS from SSA, which 
      has implications for a region where HIV and KSHV are highly prevalent. MCD-IRIS 
      may contribute to early mortality after ART initiation in SSA, and increased 
      awareness alongside improved diagnostic and treatment capacity are needed.
CI  - Copyright (c) 2022 Painschab, Mponda, Tomoka, Kampani, Chimzimu, Fedoriw and Gopal.
FAU - Painschab, Matthew S
AU  - Painschab MS
AD  - University of North Carolina (UNC) Project Malawi, Lilongwe, Malawi.
AD  - Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel 
      Hill, NC, United States.
FAU - Mponda, Marriam
AU  - Mponda M
AD  - University of North Carolina (UNC) Project Malawi, Lilongwe, Malawi.
FAU - Tomoka, Tamiwe
AU  - Tomoka T
AD  - University of North Carolina (UNC) Project Malawi, Lilongwe, Malawi.
FAU - Kampani, Coxcilly
AU  - Kampani C
AD  - University of North Carolina (UNC) Project Malawi, Lilongwe, Malawi.
FAU - Chimzimu, Fred
AU  - Chimzimu F
AD  - University of North Carolina (UNC) Project Malawi, Lilongwe, Malawi.
FAU - Fedoriw, Yuri
AU  - Fedoriw Y
AD  - University of North Carolina (UNC) Project Malawi, Lilongwe, Malawi.
AD  - Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel 
      Hill, NC, United States.
FAU - Gopal, Satish
AU  - Gopal S
AD  - Center for Global Health, National Cancer Institute, Rockville, MD, United 
      States.
LA  - eng
GR  - U54 CA190152/CA/NCI NIH HHS/United States
GR  - L30 TW011802/TW/FIC NIH HHS/United States
GR  - L30 CA233709/CA/NCI NIH HHS/United States
GR  - U54 CA254564/CA/NCI NIH HHS/United States
GR  - K01 TW011470/TW/FIC NIH HHS/United States
GR  - D43 CA260641/CA/NCI NIH HHS/United States
PT  - Case Reports
DEP - 20221212
PL  - Switzerland
TA  - Front Oncol
JT  - Frontiers in oncology
JID - 101568867
PMC - PMC9791082
OTO - NOTNLM
OT  - HIV
OT  - IRIS
OT  - KSHV
OT  - africa
OT  - malawi
OT  - multicentric castleman disease
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest. This study reflects work done while Dr. SG was employed at 
      the University of North Carolina at Chapel Hill. The opinions expressed in this 
      article are the authors own and do not reflect the view of the National 
      Institutes of Health, the Department of Health and Human Services, or the United 
      States Government.
EDAT- 2022/12/30 06:00
MHDA- 2022/12/30 06:01
PMCR- 2022/01/01
CRDT- 2022/12/29 02:40
PHST- 2022/06/14 00:00 [received]
PHST- 2022/11/24 00:00 [accepted]
PHST- 2022/12/29 02:40 [entrez]
PHST- 2022/12/30 06:00 [pubmed]
PHST- 2022/12/30 06:01 [medline]
PHST- 2022/01/01 00:00 [pmc-release]
AID - 10.3389/fonc.2022.969135 [doi]
PST - epublish
SO  - Front Oncol. 2022 Dec 12;12:969135. doi: 10.3389/fonc.2022.969135. eCollection 
      2022.